2021年10月12日简报:灭活疫苗接种后、以mRNA疫苗加强接种,中和抗体提升46.6倍;日本新冠疫情“退潮”令专家困惑;全国累计报告接种新冠疫苗22.2亿剂次

2021-10-12 MedSci整理 MedSci整理

截至北京时间2021年10月12日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过238971万例,新增295,895例,达到238,971,

截至北京时间2021年10月12日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎COVID-19)病例超过238971万例,新增295,895例,达到238,971,006例。累计死亡病例487.2万例,达到4,872,082例。新增死亡为4,416例。康复为216,214,846例,重症和危重症病人达到81,915例;全球新冠确诊病例超过100万例的国家达35个,110个国家病例超10万例。昨日报道:2021年10月11日简报:张文宏认为中国最快2022年初将有条件开放!多种哺乳动物可成为新冠宿主;新冠免疫记忆超预期

灭活疫苗接种后、以mRNA疫苗加强接种,抗体提升46.6倍

土耳其Yeditepe大学的学者在Journal of Medical Virology发表了一篇对于灭活病毒疫苗及加强接种很有意义的论文,题目是“SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen”(两剂CoronaVac疫苗接种后,以CoronaVac或BNT162b2作为第三剂接种诱导的SARS-CoV-2特异性抗体反应)。

2IVV组IgG-S的中位数是547.7 au/ml。加强接种后,3IVV组IgG-S的中位数是947.3  au/ml,是2剂CoronaVac接种的1.73倍;2IVV + BNT组IgG-S的中位数是25,538.0  au/ml,是2剂CoronaVac接种的46.6倍。用BNT162b2加强接种,诱导的IgG-S滴度是继续用CoronaVac加强接种的27倍。

当然,研究者也指出了本研究样本量较小的局限性。

德国取消全面免费新冠病毒快速测试

根据德国联邦政府和各州政府在8月10日达成的协议,德国从当地时间10月11日起正式取消全面免费的新冠病毒快速测试。除了包括儿童和特殊疾病患者在内未获疫苗接种的人群,以及在养老机构、医院、学校或工作场所工作的人群之外,普通民众进行新冠病毒快速测试均需自己承担费用。

美国部分地区新冠又一次恶化

最近几周,美国佛罗里达等南部各州的新冠病毒感染和住院人数,开始出现了大幅降低的走向,相关疫情指标均好转。

但令人担忧的是,美国北部的许多州,包括那些有较高接种疫苗比例的州,相关疫情各项指标则在恶化。

例如南方的密西西比州的新冠病毒确诊感染病人数量,从8月19日的最高点5018人,大幅降低了约95%,到10月7日只有268人。该州因新冠病毒住院的人数,从8月19日的1667人,降低至10月4日的403人。南部的阿拉巴马州、阿肯色州、乔治亚州、佛罗里达州和德克萨斯州也有着类似类似的降低走向。

例如佛蒙特州为例,7月5日的仅仅感染1人,近期增加到10月1日的286人,住院病人数量从6月份的8人,增加到9月的160人。但是该州的相关疫情数据最近一直在降低。

北达科他州感染病人数量从7月5日的143人,增加到10月7日的4485人,住院数从9人增加到184人。

一些医学专家解释说,这种变化可能是新冠病毒相关疫情季节性走向的表现。去年的情况也是这样,美国南部温暖地区的感染病人数量开始转好时,中西部北部的大部分地区、以及美国其它北部地区的感染病人数量,开始了上升。

得州州长候选人感染新冠住院,在病床上呼吁:快拒绝疫苗

得克萨斯州州长候选人、前佛罗里达州国会议员艾伦·韦斯特又因为感染新冠肺炎住院。他和华莱士稍有不同,是一位坚定且极端的反疫苗人士,在当地颇为出名。韦斯特多次控诉拜登政府利用疫苗“控制美国人”,且过度夸张新冠肺炎的危害;但此番他自己进了医院后,不少人认为这位政客应该会有所“理亏”,或者是改变自己的立场。

进了医院的韦斯特对外讲话称:感染新冠病毒住院将使他更加致力于反对接种新冠疫苗,因为自己发现除了疫苗后原来还有更多选择,将会使用单克隆抗体输注疗法来对抗新冠病毒,这非常有效。除了宣传“新疗法”外,韦斯特再次痛斥了拜登政府利用疫苗赚钱,大型制药公司和政府腐败勾结,以及自己接受单克隆抗体输注后非常好的恢复等等,他还建议其他人也接受这种治疗。报刊敏锐地发现,韦斯特的说法居然得到的支持率还不少,有相当一部分人在评论区留言要和他站在同一阵地,成为美国“最后一个打疫苗的人。”

新冠期间,针对医护人员的暴力威胁在持续增长

根据央视新闻报道,美国护士协会针对五千名护士展开问卷调查。最后,一份调查报告显示,辞职的医护人员害怕的并不是新冠病毒。31% 的受访医护人员表示,受疫情压力,医护人员遭遇的暴力威胁在持续增长。到3月份,所占比例高达22%。为了应对这样的特殊情况,已经有部分医院为医护人员准备了应急按钮,希望他们在遭遇威胁的时候能够及时对外求助,以保证自身安全。

疫情持续了一年多的时间,美国人长期处于不安中,难免会有心理负担,部分病患或者其家属就会将情绪发泄到医护人员身上。可他们似乎忘记了重要一点,如果没有这些坚守岗位的医护人员,病患根本无处就医。所以当务之急,美国人应该好好对待医护人员,保证医院能够坚持开放,接诊救治更多的病患。

澳大利亚试图与新冠病毒共存

当地时间11日,澳大利亚最大的城市悉尼自6月26日因疫情封城以来,于今日首次重新开放。在新南威尔士州 70% 的 16 岁及以上人口完全接种疫苗后,悉尼的理发店、健身房、咖啡馆和酒吧也于周一重新开放给接种了疫苗的顾客,这是 100 多天以来的首次重新开业。

目前,73.5% 的目标人群已完全接种疫苗,超过 90% 的人至少接种了一剂新冠疫苗。接种人数达到80% 为基准,澳大利亚将取消更多旅行限制,自去年3月至今,新南威尔士州居民将迎来首次出国旅行的机会。

新南威尔士州在最近 24 小时内报告了 496 例新感染病例和 8 例新冠死亡病例。但随着悉尼居民重返工作岗位并变得更加流动,感染率将会上升。

新南威尔士州州长多米尼克·佩罗特 (Dominic Perrottet) 表示,感染率和住院患者的数量是低于模型预测数量的。Perrottet 说:“因此,当我们以谨慎的方式开放限制时,这带来了希望和信心,我们处于确保人们安全非常有利的位置。虽然现在某些地区仍然存在出行限制,但如果每个人都能互相照顾并互相尊重,我们就能让人们重返工作岗位,我们可以让企业重新开业,同时确保人们的安全,”

自新冠疫情爆发18 个多月以来,澳大利亚一直与世界隔绝,关闭边境并实施严格的封锁措施,以减缓病毒的蔓延,但现在澳大利亚也正在考虑重开边境,“与病毒共存”。

日本新冠疫情“退潮”令专家困惑

日本新冠肺炎新增确诊病例数跌至近一年来的最低水平,这令卫生专家感到困惑并更担心疫情会在冬季反弹。

据报道,周一,东京的单日新增确诊病例降至87例,达到去年11月2日以来的最低水平,与8月单日新增5000多例相比出现大幅下降。8月的那波疫情重创了东京的医疗基础设施。

报道称,虽然起步缓慢,但日本的疫苗接种工作进展迅速。持续近半年的紧急隔离限制措施很可能也帮助遏制了病毒传播。然而,德尔塔变异株的传染性很强,其引发的感染和住院潮却迅速消退,这令专家们感到困惑。

日本京都大学的西浦博等人认为,夏季病例激增和随后骤降主要是人类活动的趋势造成的。

全国累计报告接种新冠疫苗22.2亿剂次

国家卫健委:截至2021年10月10日,31个省(自治区、直辖市)和新疆生产建设兵团累计报告接种新冠病毒疫苗222124.5万剂次。

日本就混合接种新冠疫苗启动研究收集数据

关于新冠疫苗接种第一剂和第二剂使用不同疫苗的“混合接种”的效果及安全性,日本政府负责支援医疗研究及分配预算的“日本医疗研究开发机构”研究班已启动验证,为防备特定疫苗停止供应等不得不接种不同产品的情况而收集数据。

报道称,该研究使用政府批准的美国辉瑞、美国莫德纳及英国阿斯利康疫苗,分为第一剂和第二剂接种不同疫苗组合的6组,以及两剂接种同一产品的3组。试验参加者为20岁以上,预计各组30人左右。接种间隔一律为四周。

参加者从接种前起到第一剂接种半年后为止定期验血,调查防止感染的抗体量等免疫反应状况。此外到接种八周后为止,还将在日志上记录症状以确认安全性。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1947432, encodeId=d687194e4321d, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Wed Mar 09 10:06:12 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078872, encodeId=6ca720e8872e6, content=<a href='/topic/show?id=f48865242bb' target=_blank style='color:#2F92EE;'>#活疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65242, encryptionId=f48865242bb, topicName=活疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sun Jan 02 07:06:12 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258105, encodeId=ffe312581058e, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Oct 13 23:06:12 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294639, encodeId=cf34129463924, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 13 23:06:12 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059899, encodeId=0519105989941, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a16c5296607, createdName=ms3000000199942802, createdTime=Tue Oct 12 19:19:50 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059699, encodeId=6ad1105969918, content=😊, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/85a6b2bf6890482c9323454efa63937b/702ba39073ef4dcca9d0d54b969a1c59.jpg, createdBy=ef7f5586135, createdName=yiqijiayou, createdTime=Tue Oct 12 10:47:20 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059685, encodeId=d1d010596854d, content=学无止境, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Oct 12 10:01:21 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1947432, encodeId=d687194e4321d, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Wed Mar 09 10:06:12 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078872, encodeId=6ca720e8872e6, content=<a href='/topic/show?id=f48865242bb' target=_blank style='color:#2F92EE;'>#活疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65242, encryptionId=f48865242bb, topicName=活疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sun Jan 02 07:06:12 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258105, encodeId=ffe312581058e, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Oct 13 23:06:12 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294639, encodeId=cf34129463924, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 13 23:06:12 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059899, encodeId=0519105989941, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a16c5296607, createdName=ms3000000199942802, createdTime=Tue Oct 12 19:19:50 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059699, encodeId=6ad1105969918, content=😊, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/85a6b2bf6890482c9323454efa63937b/702ba39073ef4dcca9d0d54b969a1c59.jpg, createdBy=ef7f5586135, createdName=yiqijiayou, createdTime=Tue Oct 12 10:47:20 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059685, encodeId=d1d010596854d, content=学无止境, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Oct 12 10:01:21 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1947432, encodeId=d687194e4321d, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Wed Mar 09 10:06:12 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078872, encodeId=6ca720e8872e6, content=<a href='/topic/show?id=f48865242bb' target=_blank style='color:#2F92EE;'>#活疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65242, encryptionId=f48865242bb, topicName=活疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sun Jan 02 07:06:12 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258105, encodeId=ffe312581058e, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Oct 13 23:06:12 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294639, encodeId=cf34129463924, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 13 23:06:12 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059899, encodeId=0519105989941, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a16c5296607, createdName=ms3000000199942802, createdTime=Tue Oct 12 19:19:50 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059699, encodeId=6ad1105969918, content=😊, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/85a6b2bf6890482c9323454efa63937b/702ba39073ef4dcca9d0d54b969a1c59.jpg, createdBy=ef7f5586135, createdName=yiqijiayou, createdTime=Tue Oct 12 10:47:20 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059685, encodeId=d1d010596854d, content=学无止境, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Oct 12 10:01:21 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1947432, encodeId=d687194e4321d, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Wed Mar 09 10:06:12 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078872, encodeId=6ca720e8872e6, content=<a href='/topic/show?id=f48865242bb' target=_blank style='color:#2F92EE;'>#活疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65242, encryptionId=f48865242bb, topicName=活疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sun Jan 02 07:06:12 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258105, encodeId=ffe312581058e, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Oct 13 23:06:12 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294639, encodeId=cf34129463924, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 13 23:06:12 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059899, encodeId=0519105989941, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a16c5296607, createdName=ms3000000199942802, createdTime=Tue Oct 12 19:19:50 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059699, encodeId=6ad1105969918, content=😊, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/85a6b2bf6890482c9323454efa63937b/702ba39073ef4dcca9d0d54b969a1c59.jpg, createdBy=ef7f5586135, createdName=yiqijiayou, createdTime=Tue Oct 12 10:47:20 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059685, encodeId=d1d010596854d, content=学无止境, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Oct 12 10:01:21 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1947432, encodeId=d687194e4321d, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Wed Mar 09 10:06:12 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078872, encodeId=6ca720e8872e6, content=<a href='/topic/show?id=f48865242bb' target=_blank style='color:#2F92EE;'>#活疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65242, encryptionId=f48865242bb, topicName=活疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sun Jan 02 07:06:12 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258105, encodeId=ffe312581058e, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Oct 13 23:06:12 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294639, encodeId=cf34129463924, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 13 23:06:12 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059899, encodeId=0519105989941, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a16c5296607, createdName=ms3000000199942802, createdTime=Tue Oct 12 19:19:50 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059699, encodeId=6ad1105969918, content=😊, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/85a6b2bf6890482c9323454efa63937b/702ba39073ef4dcca9d0d54b969a1c59.jpg, createdBy=ef7f5586135, createdName=yiqijiayou, createdTime=Tue Oct 12 10:47:20 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059685, encodeId=d1d010596854d, content=学无止境, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Oct 12 10:01:21 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
    2021-10-12 ms3000000199942802

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1947432, encodeId=d687194e4321d, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Wed Mar 09 10:06:12 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078872, encodeId=6ca720e8872e6, content=<a href='/topic/show?id=f48865242bb' target=_blank style='color:#2F92EE;'>#活疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65242, encryptionId=f48865242bb, topicName=活疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sun Jan 02 07:06:12 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258105, encodeId=ffe312581058e, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Oct 13 23:06:12 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294639, encodeId=cf34129463924, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 13 23:06:12 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059899, encodeId=0519105989941, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a16c5296607, createdName=ms3000000199942802, createdTime=Tue Oct 12 19:19:50 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059699, encodeId=6ad1105969918, content=😊, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/85a6b2bf6890482c9323454efa63937b/702ba39073ef4dcca9d0d54b969a1c59.jpg, createdBy=ef7f5586135, createdName=yiqijiayou, createdTime=Tue Oct 12 10:47:20 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059685, encodeId=d1d010596854d, content=学无止境, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Oct 12 10:01:21 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
    2021-10-12 yiqijiayou

    😊

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1947432, encodeId=d687194e4321d, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Wed Mar 09 10:06:12 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078872, encodeId=6ca720e8872e6, content=<a href='/topic/show?id=f48865242bb' target=_blank style='color:#2F92EE;'>#活疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65242, encryptionId=f48865242bb, topicName=活疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sun Jan 02 07:06:12 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258105, encodeId=ffe312581058e, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Oct 13 23:06:12 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294639, encodeId=cf34129463924, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 13 23:06:12 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059899, encodeId=0519105989941, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a16c5296607, createdName=ms3000000199942802, createdTime=Tue Oct 12 19:19:50 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059699, encodeId=6ad1105969918, content=😊, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/85a6b2bf6890482c9323454efa63937b/702ba39073ef4dcca9d0d54b969a1c59.jpg, createdBy=ef7f5586135, createdName=yiqijiayou, createdTime=Tue Oct 12 10:47:20 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059685, encodeId=d1d010596854d, content=学无止境, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Oct 12 10:01:21 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
    2021-10-12 易水河

    学无止境

    0

相关资讯

mRNA疫苗保护力5个月后大幅降低,首款新冠口服药即将获批:新冠研究新近进展

mRNA疫苗保护力5个月后大幅降低,首款新冠口服药即将获批 | 新冠研究最新进展

2021年10月5日简报:欧洲药管局批准所有成人打辉瑞加强针;卡塔尔将中国新冠疫苗列入认可疫苗清单;英国进一步简化入境政策

截至北京时间2021年10月5日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过23606万例,新增307,395例,达到236,062,47

2021年10月6日简报:美国民众反智,奇葩新冠阴谋论流行,大批民众拒绝接种疫苗;欧洲药品管理局可能开始加速评估默克的新冠口服药;新西兰宣布放弃“彻底消除新冠”战略

截至北京时间2021年10月6日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过23655万例,新增394,248例,达到236,554,40

2021年10月2日简报:国内仅哈尔滨有新增病例,厦门连续2日零新增;阿根廷批准对3岁至11岁儿童接种中国国药新冠疫苗

截至北京时间2021年10月2日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过23500万例,新增444,374例,达到235,005,38

Lancet:新冠疫苗BNT162b2预防德尔塔变体感染的有效率高达93%!

BNT162b2 疫苗在完全接种后 6 个月内具有很高的预防新冠肺炎住院的有效率,即使面对 δ 变体的广泛传播

2021年10月7日简报:张文宏认为新冠结束时间已不远!口服药,加强针成为全球重新开放的保障;全球新增新冠确诊病例和死亡人数继续下降

截至北京时间2021年10月7日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过23701万例,新增413,161例,达到237,010,37